retatrutide glucagon receptor agonist triple glp-1 gip phase 2 nejm 2023 Medscape retatrutide glucagon receptor / GLP-3:

Combining lower-dose folinic acid (200-800 mcg) with root cause treatment often outperforms other treatmentswith fewer side effects

KPV also reduces fibrotisation a formation of hard, scar-like tissue that impairs the function of affected organs and significantly reduces neuropathic pain, which occurs when nerve pathways are damaged

BMI 30.0 to 34.9 (class I obesity)

C., Guo, T., Bond, N

The decision to combine these agents must be individualized based on patient-specific factors, including medical history, current medications, cardiovascular health, and response to previous weight management interventions

Those taking anticoagulants should monitor carefully given the peptides effects on vascular systems